Abstract:Aims To explore healthcare professionals' perceptions and experiences of take‐home naloxone initiatives in acute care settings to gain an understanding of issues facilitating or impeding dispensing. Design Systematic literature review. Data Sources Cochrane, MEDLINE and CINAHL were searched from 15/03/2021 to 18/03/2021, with a follow‐up search performed via PubMed on 22/03/2021. The years 2011 to 2021 were included in the search. Review Methods A systematic literature review focused on qualitative studies and quantitative survey designs. Synthesis without meta‐analysis was undertaken using a thematic analysis approach. Results Seven articles from the United States of America (5), Australia (1) and Canada (1) with 750 participants were included in the review. Results indicate ongoing stigma towards people who use drugs with preconceived moral concerns regarding take‐home naloxone. There was confusion regarding roles and responsibilities in take‐home naloxone dispensing and patient education. Similarly, there was a lack of clarity over logistical and financial issues. Conclusion Take‐home naloxone is a vital harm reduction initiative. However, barriers exist that prevent the optimum implementation of these initiatives. Impact What is already known: Deaths due to opioid overdose are a global health concern, with take‐home naloxone emerging as a key harm reduction scheme. Globally, less than 10% of people who use drugs have access to treatment initiatives, including take‐home naloxone. An optimum point of distribution of take‐home naloxone is post‐acute hospital care. What this paper adds: There is role confusion regarding responsibility for the provision of take‐home naloxone and patient education. This is exacerbated by inconsistent provision of training and education for healthcare professionals. Logistical or financial concerns are common and moral issues are prevalent with some healthcare professionals questioning the ethics of providing take‐home naloxone. Stigma towards people who use drugs remains evident in some acute care areas which may impact the use of this intervention. Implications for practice/policy: Further primary research should examine what training and education methods are effective in improving the distribution of take‐home naloxone in acute care. Education should focus on reduction of stigma towards people who use drugs to improve the distribution of take‐home naloxone. Standardized care guidelines may ensure interventions are offered equally and take‐home naloxone 'champions' could drive initiatives forward, with support from harm reduction specialists. Reporting Method This has adhered to the PRISMA reporting guidelines for systematic reviews. Patient or Public Contribution No patient or public contribution.

Advancing the implementation of take‐home naloxone by community pharmacists: Testing the role of COM‐B

Effectiveness of direct patient outreach with a narrative naloxone and overdose prevention video to patients prescribed long-term opioid therapy in the USA: the Naloxone Navigator randomised clinical trial

A systematic review exploring healthcare professionals' perceptions of take‐home naloxone dispensing in acute care areas

Take-home naloxone administered in emergency settings: feasibility of intervention implementation in a cluster randomized trial

Is a randomised controlled trial of take home naloxone distributed in emergency settings likely to be feasible and acceptable? Findings from a UK qualitative study exploring perspectives of people who use opioids and emergency services staff

Barriers and motivational factors for engaging in novel opioid and medication disposal-related services in community pharmacies

Opioid overdose counseling and prescribing of naloxone in rural community pharmacies: A pilot study

Responsible management and use of a personal take-home naloxone supply: A pilot project

Pharmacists' perceptions regarding feasibility, acceptability, and usefulness of student-delivered naloxone education services in community pharmacy: A mixed methods study in Alabama

Readiness of community pharmacies to implement an opioid safety intervention.

Attitude changes following short-form opioid overdose video education: a pilot study

"I go out of my way to give them an extra smile now:" A study of pharmacists who participated in Respond to Prevent, a community pharmacy intervention to accelerate provision of harm reduction materials

Factors Associated with Take Home Naloxone Refusal among Emergency Department Patients Participating in an Opioid Overdose Prevention Program

Naloxone cascade of care among people who regularly inject drugs in Australia, 2020-2022

Harm Reduction in the Field: First Responders' Perceptions of Opioid Overdose Interventions

Community-led approaches to making naloxone available in public settings: Implementation experiences in the HEALing communities study

Effect of the Communities That HEAL Intervention on Overdose Education and Naloxone Distribution: A Cluster-Randomized, Wait-List Controlled Trial

Reducing perceived barriers to scaling up overdose education and naloxone distribution and medications for opioid use disorder in the United States in the HEALing (Helping End Addiction Long-Term®) communities study

Opioid Overdoses and Take-Home Naloxone Interventions: Ethnographic Evidence for Individual-Level Barriers to Treatment of Opioid Use Disorders in Rural Appalachia

Effects of Online Naloxone Training for Laypersons: An Extended-Baseline Assessment

Implementation of an EMS-based naloxone distribution program: A qualitative evaluation